Literature DB >> 62016

H-2 restriction of virus-specific cytotoxicity across the H-2 barrier. Separate effector T-cell specificities are associated with self-H-2 and with the tolerated allogeneic H-2 in chimeras.

R M Zinkernagel.   

Abstract

During infection with lymphocytic choriomeningitis or vaccinia virus, F1 irradiation chimeras reconstituted with bone marrow cells from or both parents generate cytotoxic T cells which can lyse targets across the H-2 barrier. However, activity of chimera T cells is H-2 restricted as shown by cold target competition experiments and selective restimulation of a secondary response in vitro; T cells of H-2k specificity which lyse tolerated infected H-2d target cells do not lyse infected H-2k or unrelated target cells and vice versa. Therefore, H-2 restriction of virus-specific cytotoxic T cells probably does not reflect need for like-like self-interactions for lysis to occur. The specificity of virus immune T cells is thus determined by the H-2K and H-2D specificities present in the infected animal and which are probably recognized unidirectionally by T cells. The results are compatible with the idea the T cells are specific for "altered alloantigen", i.e., a complex of cell surface marker and viral antigen. Alternatively, explained with a dual recognition model, T cells may possess two independently, clonally expressed receptors, a self-recognizer which is expressed for one of the syngeneic or tolerated allogeneic K or D "self" markers, and an immunologically specific receptor for viral antigen.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62016      PMCID: PMC2190437          DOI: 10.1084/jem.144.4.933

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  Cytotoxic T lymphocytes recognise allogeneic tolerated TNP-conjugated cells.

Authors:  H Von Boehmer; W Haas
Journal:  Nature       Date:  1976-05-13       Impact factor: 49.962

2.  Virus-specific T-cell-mediated cytotoxicity across the H-2 barrier to virus-altered alloantigen.

Authors:  R M Zinkernagel
Journal:  Nature       Date:  1976-05-13       Impact factor: 49.962

Review 3.  The somatic generation of immune recognition.

Authors:  N K Jerne
Journal:  Eur J Immunol       Date:  1971-01       Impact factor: 5.532

4.  F1 hybrid animals: reactivity against recognition structures of parental strain lymphoid cells.

Authors:  H Ramseier; J Lindenmann
Journal:  Pathol Microbiol (Basel)       Date:  1969

5.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

6.  An improved system for the assay of stimulation in mouse mixed leucocyte cultures.

Authors:  K Lafferty; M Ryan; I Misko
Journal:  J Immunol Methods       Date:  1974-03       Impact factor: 2.303

Review 7.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

8.  Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system.

Authors:  F Plata; J C Cerottini; K T Brunner
Journal:  Eur J Immunol       Date:  1975-04       Impact factor: 5.532

9.  Cell interactions between histoincompatible T and B lymphocytes. VII. Cooperative responses between lymphocytes are controlled by genes in the I region of the H-2 complex.

Authors:  D H Katz; M Graves; M E Dorf; H Dimuzio; B Benacerraf
Journal:  J Exp Med       Date:  1975-01-01       Impact factor: 14.307

10.  Genetic control of the antibody response to poly-L(Tyr,Glu)-poly-D,L-Ala--poly-L-Lys in C3H--CWB tetraparental mice.

Authors:  K B Bechtol; J H Freed; L A Herzenberg; H O McDevitt
Journal:  J Exp Med       Date:  1974-12-01       Impact factor: 14.307

View more
  26 in total

Review 1.  Lymphocytes. 2. Differentiation. Differentiation of lymphoid precursor cells.

Authors:  G Janossy; G Pizzolo
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

2.  Immune effector cell activity in canines: failure to demonstrate genetic restriction in direct antiviral cytotoxicity.

Authors:  C K Ho; L A Babiuk; B T Rouse
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

3.  Primary in vitro sensitization of virus specific cytotoxic T lymphocytes.

Authors:  H Jung; K Pfizenmaier; A Starzinski-Powitz; M Röllinghoff; H Wagner
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

4.  Tumour markers in urology: aids in cancer diagnosis and management.

Authors:  B Wahren
Journal:  Urol Res       Date:  1979-06-22

5.  Immunological evaluation of asymptomatic carriers of hepatitis B virus.

Authors:  Y Levo; D Shouval; R Tur-Kaspa; S Wollner; S Penchas; A Zlotnick; M Eliakim
Journal:  Clin Exp Immunol       Date:  1981-04       Impact factor: 4.330

6.  Periodic loss of reactivity of a myeloma tumor with cytotoxic thymus-derived lymphocytes.

Authors:  J H Russell; A H Hale; L C Ginns; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

7.  T cell-mediated immune responses of lupus-prone BXSB mice and other murine strains.

Authors:  W D Creighton; R M Zinkernagel; F J Dixon
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

8.  Induction of cytolytic T- and B-cell responses against influenza virus infections.

Authors:  D Armerding; H Rossiter
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

9.  Specificity studies on cytotoxic thymus-derived lymphocytes reactive with influenza virus-infected cells: evidence for dual recognition of H-2 and viral hemagglutinin antigens.

Authors:  F A Ennis; W J Martin; M W Verbonitz; G M Butchko
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

10.  Toward a molecular understanding of adaptive immunity: a chronology, part I.

Authors:  Kendall A Smith
Journal:  Front Immunol       Date:  2012-12-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.